Abnormalities in cellular dierentiation are frequent occurrences in human cancers. Treatment of human melanoma cells with recombinant ®broblast interferon (IFN-b) and the protein kinase C activator mezerein (MEZ) results in an irreversible loss in growth potential, suppression of tumorigenic properties and induction of terminal cell dierentiation. Subtraction hybridization identi®ed melanoma dierentiation associated gene-7 (mda-7), as a gene induced during these physiological changes in human melanoma cells. Ectopic expression of mda-7 by means of a replication defective adenovirus results in growth suppression and induction of apoptosis in a broad spectrum of additional cancers, including melanoma, glioblastoma multiforme, osteosarcoma and carcinomas of the breast, cervix, colon, lung, nasopharynx and prostate. In contrast, no apparent harmful eects occur when mda-7 is expressed in normal epithelial or ®broblast cells. Human clones of mda-7 were isolated and its organization resolved in terms of intron/exon structure and chromosomal localization. Humda-7 encompasses seven exons and six introns and encodes a protein with a predicted size of 23.8 kDa, consisting of 206 amino acids. Hu-mda-7 mRNA is stably expressed in the thymus, spleen and peripheral blood leukocytes. De novo mda-7 mRNA expression is also detected in human melanocytes and expression is inducible in cells of melanocyte/melanoma lineage and in certain normal and cancer cell types following treatment with a combination of IFN-b plus MEZ. Mda-7 expression is also induced during megakaryocyte dierentiation induced in human hematopoietic cells by treatment with TPA (12-O-tetradecanoyl phorbol-13-acetate). In contrast, de novo expression of mda-7 is not detected nor is it inducible by IFN-b+MEZ in a spectrum of additional normal and cancer cells. No correlation was observed between induction of mda-7 mRNA expression and growth suppression following treatment with IFN-b+MEZ and induction of endogenous mda-7 mRNA by combination treatment did not result in signi®cant intracellular MDA-7 protein. Radiation hybrid mapping assigned the mda-7 gene to human chromosome 1q, at 1q 32.2 to 1q41, an area containing a cluster of genes associated with the IL-10 family of cytokines. Mda-7 represents a dierentiation, growth and apoptosis associated gene with potential utility for the gene-based therapy of diverse human cancers. Oncogene (2001) 20, 7051 ± 7063.
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Introduction
Cancer is a progressive disease in which evolving tumor cells exhibit profound changes in gene expression that occur in a temporal manner (DeRisi et al., 1996; Schena et al., 1996; Ross et al., 2000) . These include, activation of genes serving as positive regulators of the cancer phenotype, oncogenes; inactivation of genes functioning as inhibitors of the cancerous state, tumor suppressor genes; and altered expression of genes that act at a later stage in cancer development resulting in increased cancer aggressiveness which can culminate in metastasis, progression modulating genes (Fisher, 1984; Bishop, 1991; Vogelstein and Kinzler, 1991; Su et al., 1997 Su et al., , 1999 Kang et al., 1998) . Extensive eort is being directed toward identifying and characterizing the genetic elements that contribute to cancer development and evolution. Achieving this goal oers promise for identifying genomic targets for improved cancer diagnosis and therapy.
A failure to display normal patterns of dierentiation is common in many cancer subtypes (Jiang et al., 1994; Waxman, 1996) . Recent experimental approaches have targeted this defect in cancer cells by using agent(s) that modify tumor growth by inducing terminal dierentiation, a process termed`dierentiation therapy' (Waxman, 1996) . Although several models exist to explain how metastatic melanoma cells develop, a widely accepted scheme involves a linear set of changes from melanocyte to nevus to primary melanoma [radial growth phase (RGP) to vertical growth phase (VGP)] to metastatic melanoma (Clark, 1991; Armstrong and Kricker, 1994; Herlyn et al., 2000) . This process is associated with profound changes in cellular physiology and gene expression suggesting temporal modi®cations in the dierentiation of cells as this tumor evolves (Jiang et al., 1995a; Huang et al., 1999a,b; Herlyn et al., 2000) . In human melanoma cells, the combination of recombinant human IFN-b plus the protein kinase C activator MEZ results in an irreversible loss in proliferative ability concluding in terminal cell dierentiation (Fisher et al., 1985; . Combining this model system with subtraction hybridization resulted in the identi®cation and cloning of several genes regulated during the process of growth arrest and terminal dierentiation, i.e., melanoma dierentiation associated (mda) and dierentiation induction subtraction hybridization (DISH) genes Jiang et al., 1995a Jiang et al., ,b, 2000 Huang et al., 1999a,b; Kang et al., 2001) .
A speci®c mda gene, mda-7, displays elevated mRNA expression in melanocytes and nevi, reduced mRNA expression in RGP and early VGP melanoma lesions and little or no mRNA expression in late VGP and metastatic melanoma (Jiang et al., 1995b) . Moreover, ectopic expression of mda-7 in human melanoma cells results in growth suppression, without induction of terminal dierentiation (Jiang et al., 1995b) . When expressed at high levels, by means of an adenovirus expression system, mda-7 induces growth suppression and programmed cell death (apoptosis) in a broad spectrum of human cancers, including carcinomas of most tissue origins Madireddi et al., 2000c; Saeki et al., 2000; Mhashilkar et al., 2001) . In contrast, mda-7 has a negligible eect on growth and does not induce apoptosis in normal epithelial and ®broblast cells (Jiang et al., 1996; Su et al., 1998; Madireddi et al., 2000c; Saeki et al., 2000; Mhashilkar et al., 2001 ). These ®ndings indicate that this novel cancer growth suppressing and apoptosis-inducing gene may have wide applications for the gene-based therapy of multiple human cancers (Jiang et al., 1996; Su et al., 1998; Madireddi et al., 2000c; Saeki et al., 2000; Mhashilkar et al., 2001) .
Studies designed to de®ne the mechanism of mda-7 gene expression regulation during human melanoma terminal dierentiation document that the mda-7 promoter is constitutively active in human melanoma cells and treatment with IFN-b+MEZ does not signi®cantly alter promoter function (Madireddi et al., 2000a,b) . In contrast, mda-7 mRNA levels during terminal dierentiation are partly regulated by dierential post-transcriptional-message stabilization dictated by the AU-rich (ARE) sequences present in the 3'-untranslated region of the mda-7 cDNA (Madireddi et al., 2000a) . To further characterize this cancer suppressor gene we have isolated mda-7 genomic DNA from human cells and de®ned its gene structure and analysed endogenous and inducible expression in melanocyte/melanoma and other lineage cells. Expression of mda-7 is restricted to speci®c normal tissues, including thymus, spleen and blood (peripheral blood leukocytes), and certain cell types, including melanocytes, nevi and some early stage melanomas. Enhanced mda-7 expression is also induced in melanoma cells following treatment with IFN-b+MEZ, in K562 erythroleukemia cells treated with TPA and in speci®c human normal and cancer cells following treatment with IFN-b+MEZ. These results demonstrate for the ®rst time that appropriate treatment(s) can induce mda-7 mRNA in a spectrum of normal and cancer cells, in addition to melanoma cells, which do not express detectable levels of mda-7 mRNA de novo. The level of mda-7 mRNA induced, as well as the level of MDA-7 protein, is signi®cantly less following IFN-b+MEZ treatment than infection with a replication defective adenovirus expressing mda-7, Ad.mda-7. Moreover, IFN-b+MEZ inhibits growth in a panel of normal and cancer cells and this eect does not correlate with induction of mda-7 mRNA, but rather corresponds with IFN-b treatment which does not induce mda-7 mRNA. The chromosomal location of human mda-7 was determined and found to reside within a region of human chromosome 1q, 1q 34.2 to 1q41, which corresponds with a genomic locus containing several members of the interleukin-10 family of cytokines.
Results
Genomic structure and chromosomal localization of mda-7 to a genomic region containing an interleukin-10 related gene cluster
Restriction fragment analyses of human genomic DNA demonstrate that the human mda-7 gene is a single copy gene. Southern blot analyses reveal a single band upon hybridization with a mda-7 cDNA probe (Jiang et al., 1995b) . Based on its unique presence in the human genome, a PCR-based method using mda-7 gene speci®c primers was used to identify and isolate its genomic DNA. Human genomic DNA from diploid ®broblasts (Clontech) was used as a template in a polymerase chain reaction ampli®cation protocol with mda-7 gene speci®c primers corresponding to the 5' and 3' untranslated regions. Agarose gel electrophoresis analyses identi®ed a 5.5 Kbp ampli®cation product, which was cloned into pBluescript, and the nucleotide sequence was obtained. In order to obtain genomic sequence information¯anking the PCR generated fragment a human placental genomic library (Stratagene) was screened. Five clones were isolated from 2610 6 plaques of human placental genomic library using an mda-7 cDNA probe. Restriction enzyme digestion and probing with 5'-and 3'-UTR speci®c sequences revealed that one of the clones encompasses the entire reading frame of the mda-7 gene. This phage clone was puri®ed and sequenced using mda-7 gene speci®c primers. Using the two methods described above a contiguous mda-7 genomic sequence was obtained. The mda-7 transcription unit is 6.33 Kbp, subsequent DNA walking resulted in the cloning of an additional 2.2 Kbp of the 5'-¯anking region which contains the mda-7 promoter (Madireddi et al., 2000a) . The nucleotide sequence of human mda-7 and exon/ intron boundaries are shown in Figure 1 . The mda-7 cDNA deduced from the human exon sequence information corresponded exactly with the previously reported human mda-7 cDNA (Jiang et al., 1995b) .
The identi®ed intron ± exon boundaries conform to the consensus splicing signals (GT_AG). These dinucleotide sequences are putative splice sites implicated in primary transcript splicing (Breathnach et al., 1978; Breathnach and Chambon, 1981) . The exons range in size from 64 to 889 bp while the introns range from 115 to 1443 bp. The transcriptional start site was mapped by 5' RACE using total RNA from terminally dierentiated HO-1 human melanoma cells (Jiang et al., 1995b) . Primer extension analysis produced similar results (data not shown), and the transcription start site was designated, and its position is shown in Figure  1 . Analyses of the 5'-upstream nucleotide sequence reveals the presence of a TATA element at position 730 to 725 (Figure 1 ). Elimination of this TATA element resulted in a complete loss in promoter activity (Madireddi et al., 2000a) .
A panel of rodent ± human hybrid DNAs containing most human chromosome regions were tested for the presence of the mda-7 locus by a PCR ampli®cation based method. Hybrid DNAs were scored positive if they contained a 129 bp human mda-7 speci®c product. Hybrids retaining chromosome region 1q showed a mda-7 speci®c product (data not shown). To further re®ne the localization of mda-7, the Stanford and Genebridge radiation hybrid DNAs (Research Genetics) were tested. No linkage was found using the Stanford radiation hybrid DNAs. Using the Genebridge radiation hybrids and the WICGR mapping server (www.genome.wi.mit.edu/cgibin/contig/rhmapper.pl) mda-7 displayed very close linkage to markers WI-9641 (D1S306) and D1S491, which map to the region 1q32.2-q41 (data not shown). The genomic locus encoding mda-7 appears to be within a IL-10 related gene cluster containing four genes including IL-10, IL-19, IL-20 and mda-7 in linear order spanning 195 kb of genomic DNA (Blumberg et al., 2001) . The functional implications of this arrangement are presently unclear.
Mda-7 displays restricted expression in normal tissue and inducible expression in human erythroleukemia cells Multiple tissue Northern blot analyses of human tissue poly(A) + RNA (Clontech R ) reveals that mda-7 expression is restricted to those tissues associated with the immune system such as, spleen, thymus and peripheral blood leukocytes (Figure 2a ). These ®ndings are in agreement with the observations made by Soo et al. (1999) who reported signi®cantly elevated (9 ± 12-fold) levels of c49a (rat homologue of mda-7) mRNA during wound healing, speci®cally in areas surrounding the edge of the wound. To further analyse this relationship the incidence of mda-7 expression in hematopoietic Figure 1 Human mda-7 genomic structure. The nucleotide sequence of all exons including non-coding 5' and 3' UTR sequences and coding exons are shown in bold type. Sequences anking the exon/intron junction including the splice consensus GT-AG sequences are indicated in normal type and shadow font respectively. Length of each intron and other landmark sequences including transcription start site (+1), putative TATA regulatory sequence, translation initiator codon (ATG) and polyadenylation consensus sequence are highlighted at the respective positions (erythroid, myeloid and lymphoid) cell dierentiation was analysed. Northern blotting analyses of total RNA from leukemic cell lines induced to dierentiate with TPA were performed. The results of this study reveal an increase in mda-7 mRNA levels in the leukemic cell line, K562 (erythroleukemia), when it is induced to dierentiate into megakaryocytes upon treatment with TPA ( Figure 2b ). Mda-7 mRNA expression in dierentiated K562 cells ( Figure 2b , lane 5) is similar to that found in terminally dierentiated HO-1 human melanoma cells after correction for variations in total RNA based on the levels of rRNA ( Figure 2b , lane 9). In contrast, HL-60 (human promyelocytic leukemia) induced to dierentiate with TPA (monocyte/macrophage) or DMSO (granulocyte), CEM-C7 (human Tcell leukemia) treated with TPA and HL534 (TPAresistant HL-60 cell variant) (Tonetti et al., 1992) did not express mda-7 in the absence or presence of inducer ( Figure 2b ).
De novo expression of mda-7 occurs in normal and immortalized human melanocytes and is readily inducible in most human melanoma cell lines
Experiments have been performed to examine mda-7 expression pro®les in normal and cancer-derived human cell types. In previous studies, expression of mda-7 mRNA was detected using Northern blotting in an SV40-immortalized human melanocyte cell line (FM516-SV) and in one of six metastatic melanoma cell lines (Jiang et al., 1995b) . In addition, using patient-derived samples, including melanocytes (®ve samples), primary melanomas (seven RGP and early VGP samples) and metastatic melanomas (seven samples), an inverse correlation between melanoma progression and mda-7 RNA expression was apparent using RT ± PCR based approaches, with highest levels in melanocytes, deceasing levels in primary melanomas and lowest levels in metastatic melanomas (Jiang et al., 1995b) . Previous studies demonstrated that treatment of metastatic melanoma cells with IFN-b+MEZ for 24 h resulted in induction or enhanced mda-7 mRNA expression in the six metastatic melanoma cell lines analysed (Jiang et al., 1995b) . These studies have now been extended to include normal early passage melanocytes and a series of additional melanoma cell lines, including WM35 (an early RGP melanoma), WM278 (an early VGP melanoma) and additional metastatic melanoma cell lines (SK-MEL p53 wt, SK-MEL p53 mt, MeWo, 3S5, 70W, WM239 and C8161) ( Figure 3 ). In these cells, elevated mda-7 mRNA was only apparent de novo in normal melanocytes, with lower levels of de novo expression in WM35 and F0-1 cells. However, 24 h treatment with IFN-b+MEZ resulted in a dierential enhancement or induction of mda-7 expression in all of the melanocyte/melanoma cell lines with the exception of SK-MEL p53 mt (containing a mutant p53 gene) ( Figure 3 ). Additionally, the induction of mda-7 in C8161 cells was signi®cantly blunted in comparison with the other metastatic melanoma cell lines. It does not appear that The indicated cell types were grown for 24 h in the presence of 2000 units/ml of IFN-b+10 ng/ml of MEZ, total RNA was isolated and analysed by Northern blotting and probing with a 32 P-labeled mda-7 cDNA probe. The blot was stripped and then reprobed with a 32 P-labeled GAPDH probe. FM516 is an SV40-immortalized normal melanocyte cell line (FM516-SV); WM35 is an early RGP primary melanoma cell line; WM278 is an early VGP primary melanoma cell line; WM239, FO-1, C8161, MeWo, 3S5 and 70W are metastatic melanoma cell lines; SK-MEL p53 mt is a metastatic melanoma cell line with a con®rmed mutant p53 genotype; and SK-MEL p53 wt is a metastatic melanoma cell line with a con®rmed wild-type p53 genotype having a mutant p53 gene by itself can prevent mda-7 expression, since MeWo and its two subclones, 3S5 displaying a reduction in metastatic competence and 70W exhibiting enhanced metastatic potential (Kerbel and Man, 1984; Graham et al., 1991) , which contain one mutant and one wild-type p53 allele are readily inducible for mda-7 expression following IFN-b+MEZ treatment. These studies document de novo expression of mda-7 in cultured normal human melanocytes, as observed with patient-derived melanocytes, and they provide additional support for the idea that mda-7 may function as a negative regulator of melanoma progression (Jiang et al., 1995b) .
Induction of mda-7 mRNA is not restricted to human melanoma cells, but can occur in various normal and cancer-derived human cell lines following treatment with IFN-b+MEZ Previous studies and those described above document a clear association between mda-7 mRNA expression and melanocyte/melanoma lineage cells. To determine if mda-7 expression is restricted to this cell subtype or if de novo or inducible expression occurs in additional cell types, a panel of normal and cancer-derived cells were analysed for mda-7 mRNA expression with and without a 24 h treatment with IFN-b+MEZ ( Figure  4 ). In the case of normal human prostate epithelial and human prostate carcinoma cells no expression was apparent, with or without treatment with IFNb+MEZ, in normal early passage prostate epithelial cells (HuPEC) or in two of three prostate carcinoma cell lines, i.e., LNCaP and PC-3 (Figure 4a ). In contrast, although not expressed de novo, 24 h exposure to IFN-b+MEZ resulted in induction of mda-7 mRNA expression in DU-145 human prostate carcinoma cells. Since DU-145 cells contain a mutant form of the tumor suppressor protein RB and they also contain a mutation in p53, induction of mda-7 can occur in speci®c prostate cancer cells defective in these tumor suppressor proteins. In the case of breastderived epithelial cells, mda-7 mRNA expression was not detected de novo in six cell lines, but it was inducible by IFN-b+MEZ treatment in normal HBL-100 cells and in p53 mutant MDA-MB-231 and p53-null MDA-MB-157 cells (Figure 4b ). In contrast, expression of mda-7 was not apparent in untreated or combination treated MCF-7 (wild-type p53), T47D (mutant p53) or MDA-MB-453 (mutant p53) breast carcinoma cell lines. Further analysis indicates that mda-7 is also inducible by IFN-b+MEZ in normal human cerebellum cells (NC cell line), one of two human glioblastoma multiforme cell lines (GBM-18, but not T98G), a human cervical carcinoma cell line (HeLa), a human nasopharyngeal carcinoma cell line (HONE-1) and a human osteosarcoma cell line (Saos2, which is null for both RB and p53) (Figure 4c ). In contrast, no expression, with or without combination treatment, was apparent in SW613 human colon carcinoma or BxPC-3, PANC-1, MIA PaCa-2 or AsPC-1 human pancreatic carcinoma cells (Figure 4c and data not shown). These results demonstrate that mda-7 is not expressed de novo in most normal and cancer cell types, but expression, at least at an mRNA level, can be induced by IFN-b+MEZ in a spectrum of normal and tumor cell types independent of alterations in Rb and/or p53 genotypes.
Based on the ability of IFN-b+MEZ to induce mda-7 mRNA expression in cells other than melanoma, experiments were performed to evaluate the functional signi®cance of this treatment protocol in combination treated cells. Studies were performed to determine if induction of mda-7 mRNA correlated with expression of MDA-7 protein. To address this question FM516-SV (constitutively express mda-7 mRNA) and HO-1 and DU-145 (which are inducible for mda-7 mRNA) were either infected with 1, 10, 50 or 100 pfu/cell of Ad.mda-7, a replication incompetent adenovirus expressing the coding region of the mda-7 gene , or treated with 2000 units/ml IFN-b+10 ng/ml MEZ, and the amount of mda-7 mRNA and MDA-7 protein was determined by Northern and Western blotting, respectively (Figures 5 and 6 ). These studies indicate quantitative dierences in the levels of mda-7 mRNA and/or MDA-7 protein in the three dierent cell types with and without infection with Ad.mda-7 or treatment with IFN-b+MEZ. In the case of DU-145, infection with Ad.mda-7 results in a dose-dependent expression of mda-7 mRNA and MDA-7 protein, with intracellular protein readily detected 24 h following infection with 50 or 100 pfu/cell but not with 1 or 10 pfu/cell (Figures 5 and 6 ). In contrast, the level of mda-7 mRNA following infection with 1 pfu/cell of Ad.mda-7 is *twofold higher than observed after treatment of DU-145 with IFN-b+MEZ and no intracellular protein is detected in these cells after 24 h treatment (Figure 6 ). In the case of FM516-SV, mda-7 mRNA is detectable de novo at a lower level than observed following infection with 1 pfu/cell of Ad.mda-7 and treatment with IFN-b+MEZ elevates mda-7 mRNA in these cells ( Figure 5 ). With respect to protein, no MDA-7 protein is detected in IFNb+MEZ treated cells and signi®cantly less MDA-7 protein than detected in Ad.mda-7-infected DU-145 cells is present in FM516-SV cells infected with 50 or 100 pfu/cell of Ad.mda-7 (Figure 6 ). In HO-1, no mda-7 mRNA is present de novo and treatment with IFNb+MEZ results in induction of mda-7 mRNA at levels that exceed those observed following infection with 1 pfu/cell of Ad.mda-7 ( Figure 5 ). In comparison with DU-145 and FM516-SV, infection of HO-1 cells with Ad.mda-7 results in less mda-7 mRNA and MDA-7 protein, with intracellular protein only detected after infection with 100 pfu/cell of Ad.mda-7 (Figures 5 and  6 ). These results indicate dierences in the levels of mda-7 mRNA and intracellular MDA-7 protein following Ad.mda-7 infection in the three dierent cell types, which may re¯ect dierences in viral infectivity or kinetics of transgene expression. Moreover, the levels of intracellular MDA-7 protein resulting from treatment with IFN-b+MEZ are minimal in all three cell types. Further studies are required to determine if the levels of secreted MDA-7 protein dier in these Figure 5 for 24 h and levels of MDA-7 and EF-1a proteins in total cell lysates were determined by Western blotting using the appropriate polyclonal or monoclonal antibody, respectively cells upon treatment with IFN-b+MEZ and/or following infection with Ad.mda-7.
Previous studies in HO-1 melanoma cells demonstrate a small induction of mda-7 mRNA following treatment with MEZ and a major induction of mda-7 mRNA following treatment with IFN-b+MEZ (Jiang et al., 1995b; Madireddi et al., 2000a,b) . In contrast, IFN-b does not induce mda-7 expression in HO-1 cells. To determine if a similar mda-7 induction pro®le is apparent in non-melanoma cell types induced to express mda-7 mRNA following treatment with IFNb+MEZ the eect of treatment with IFN-b and MEZ on mda-7 expression in DU-145 and HeLa cells was determined. The combination of IFN-b+MEZ induced mda-7 mRNA in both cell types, whereas no induction of mda-7 mRNA occurred after MEZ or IFN-b treatment (data not shown). These results provide additional evidence that the combination treatment with IFN-b+MEZ is a more eective inducer of mda-7 mRNA than either agent used independently.
An important question is the physiological relevance of induction of mda-7 by IFN-b+MEZ in speci®c cell types. To begin addressing this issue, we have compared the eect of IFN-b, MEZ and IFNb+MEZ on 48 and 96 h growth and viability in cells displaying variable induction or no induction of mda-7 after combination treatment (Figures 7 and 8) . When administered at 10 ng/ml, MEZ did not inhibit the growth and in some cases even stimulated growth which was cell type speci®c. However, treatment with 2000 units/ml of IFN-b, alone or in combination with MEZ signi®cantly inhibited growth, an eect that was apparent to dierent extents by 48 h in all the cell types tested (Figures 7 and 8 ). With many of the cell types, the combination of IFN-b+MEZ induced greater growth suppression, and in some cases a decrease in cell viability, than either agent used alone. Growth suppression and decreased viability was apparent in cells displaying inducible mda-7 mRNA expression as well as in cells not showing inducible mda-7 mRNA expression, such as MCF-7 and SK-MEL p53 mt. These results, and studies demonstrating that IFN-b decreases growth without inducing mda-7, indicate that induction of mda-7 by IFN-b+MEZ is not mandatory for growth suppression and decreasing viability in combination treated cells.
Discussion
Treatment of human melanoma cells with IFNb+MEZ results in profound physiological changes, including an irreversible loss in proliferative potential, suppression of oncogenic potential in athymic nude mice, altered cell surface antigenicity, temporal alterations in gene expression and induction of terminal dierentiation (Fisher et al., 1985; Graham et al., 1991; Jiang et al., , 1994 Jiang et al., , 1995a Jiang et al., ,b, 2000 Huang et al., 1999a,b; Kang et al., 2001; Leszczyniecka et al., 2001) . To obtain insights into this process we have begun to de®ne the spectrum of gene expression changes occurring as a consequence of this combination treatment in human melanoma cells using several molecular approaches. These include, construction of temporally spaced subtracted cDNA libraries from IFN-b+MEZ treated HO-1 melanoma cells combined with random clonal isolation, high density microarray analysis of subtracted cDNA clones and reverse Northern hybridization of randomly isolated subtracted cDNA clones Jiang et al., 1994; Huang et al., 1999a,b) . In addition, we have applied a new and highly ecient rapid subtraction hybridization, RaSH, protocol to address the question of temporal gene expression changes occurring during the induction of terminal dierentiation in human melanoma cells, resulting in the cloning of additional previously identi®ed and novel genes implicated in this process (Jiang et al., 2000; Kang et al., 2001) . These studies have proven very informative and are providing a molecular snapshot of genes involved in cancer growth control, survival, apoptosis and dierentiation (Huang et al., 1999a,b; Jiang et al., 2000; Leszczyniecka et al., 2001) .
A potentially relevant gene in melanoma progression, isolated by subtraction hybridization, is mda-7 (Jiang et al., 1995b) . When originally cloned, it was proposed that mda-7 might function as a tumor suppressor gene in the context of melanocyte/melanoma cells, displaying elevated expression in normal melanocytes but decreased expression in primary melanoma cells and a further diminution in expression as melanomas progress to a metastatic state (Jiang et al., 1995b) . If was further suggested that expression of mda-7 in the context of normal melanocytes might contribute to the slower growth rate of these cells versus melanoma cells (Jiang et al., 1995b) . Two lines of evidence con®rm an inverse relationship between growth rate and mda-7 expression in speci®c cell types. Expression of an inducible mda-7 construct in human melanoma cells decreases growth rate and antisense inhibition of mda-7 expression in human cervical cancer (HeLa) cells engineered to express mda-7 enhances their growth rate (Jiang et al., 1995b (Jiang et al., , 1996 . A hallmark of the terminal dierentiation process is growth suppression. When mda-7 is expressed at physiological levels in melanoma cells by DNA transfection growth is suppressed, whereas expression of mda-7 at supraphysiological levels in melanoma cells following viral (Ad.mda-7) infection induces apoptosis (Madireddi et al., 2000c) . In contrast, neither of these treatment protocols with mda-7 results in terminal dierentiation in human melanoma cells. These observations suggest that additional genes working in combination with mda-7 or operating independently of mda-7 are involved in initiating and maintaining terminal dierentiation in human melanoma cells following IFN-b+MEZ treatment.
The present study provides additional support for an inverse correlation between mda-7 expression and human melanocyte to melanoma progression. Normal early passage human melanocytes and SV40-immorta-lized normal human melanocytes express mda-7 de novo as does WM35 cells (an early RGP primary melanoma cell line) (Figure 3 ). In contrast, only one of nine metastatic melanoma cells displayed endogenous mda-7 expression, and in the one positive melanoma cell line, FO-1, expression was lower than observed in the normal melanocytes or WM35 cells (Figure 3 ). When treated with IFN-b+MEZ for 24 h, mda-7 mRNA expression was elevated in normal early passage human melanocytes, SV40-transformed human melanocytes (FM516-SV) and WM35 cells and expression was induced in eight of the nine metastatic melanoma cells. In general, no correlation was found between the level of induction of mda-7 by IFN-b+MEZ and the degree of growth-suppression in the melanocyte/melanoma cell lines, with the possible exceptions of C8161 and SK-MEL p53 mt cells which showed low-level or no induction of mda-7, respectively, and were more resistant to growth suppression and decreased viability than the other metastatic melanoma cell lines displaying elevated levels of mda-7 expression following combination treatment (Figure 7 ). These ®ndings support the hypothesis that mda-7 may only partially contribute to the growth and dierentiation changes observed in human melanoma cells after treatment with IFN-b+MEZ. Alternatively, mda-7 may exert eects on cellular physiology that are dierent in the context of a melanocyte versus a melanoma. This possibility is strengthened by the observation that Ad.mda-7 does not signi®cantly alter growth in normal melanocytes, whereas it induces growth suppression and apoptosis in metastatic human melanoma cells (unpublished data).
Analysis of de novo mda-7 mRNA expression in a panel of normal and cancer cell types demonstrates limited expression in a normal cellular context, such as melanocyte, with little or no expression in cancer cells. The lack of expression in a cancer cell background supports the possibility that mda-7 may function as a cancer growth suppressor and inactivation or decreased expression of this gene may contribute to the cancer phenotype. The lack of de novo expression of mda-7 in most cancer cells could result because of permanent defects in the gene or pathways leading to stable mRNA expression, or alternatively could re¯ect a lack of expression based on cellular milieu or the physiological state of the cell. It does not appear that the lack of mda-7 expression in cancer cells results from mutations in the mda-7 gene since no changes have been observed in a spectrum of cancer and normal cells (Soo et al., 1999; Mhashilkar et al., 2001) . At least a partial answer comes from previous studies in melanoma cells which suggest that the mda-7 promoter is constitutively active in melanoma cells, whereas mda-7 mRNA expression is restricted to melanoma cells treated with IFN-b+MEZ and induced to terminally dierentiate (Madireddi et al., 2000a,b) . These ®ndings suggest that post-transcriptional modi®cations may contribute to mda-7 mRNA levels in human melanoma cells (Madireddi et al., 2000a) . To address the question of cell context speci®c expression of mda-7 we have evaluated the eect of IFN-b+MEZ on mda-7 mRNA expression in a panel of normal and cancer cell types (Figure 4) . In addition to induction of mda-7 expression in most melanomas and constitutive expression of mda-7 in normal melanocytes and WM35 RGP cells, treatment with IFN-b+MEZ for 24 h induced mda-7 expression in normal human cerebellum cells (NC), one of two human glioblastoma multiforme cell lines (GBM-18), a human nasopharyngeal carcinoma cell line (HONE-1), a human cervical carcinoma cell line (HeLa), one of three human prostate carcinoma cell lines (DU-145), a normal human breast epithelial cell line (HBL-100), two of ®ve human breast carcinoma cell lines (MDA-MB-157 and MDA-MB-231) and a human osteosarcoma cell line (Saos-2) (Figure 4) . To determine the functional signi®cance of this mRNA induction, we determined levels of MDA-7 protein following treatment of FM516-SV, HO-1 and DU-145 cells with IFN-b+MEZ. For comparison, the same cell types were infected with 1, 10, 50 or 100 pfu/ cell of Ad.mda-7, which contains the coding region of mda-7 without the 3' or 5' regions of this gene . Infection with Ad.mda-7 resulted in a dosedependent induction of both mda-7 mRNA and MDA-7 protein, with the highest expression in DU-145 cells and reduced expression in FM516-SV and HO-1 cells (Figures 5 and 6 ). In contrast, treatment with IFNb+MEZ eciently induced mda-7 mRNA, with the level of induction being comparable to low levels of Ad.mda-7 infection (1 pfu/cell), which did not result in readily detectable intracellular MDA-7 protein ( Figure  6 ). These results suggest that the level of endogenous MDA-7 protein resulting following treatment of speci®c cells with IFN-b+MEZ for 24 h is small and may not correlate with the increase or induction in mda-7 mRNA. These results suggest a potential role for post-transcriptional processes in regulating endogenous MDA-7 protein levels in cells. Further studies are also required to determine if there are dierences in the stability and/or secretion of endogenously produced MDA-7 protein versus virally generated MDA-7 protein.
Evaluation of mda-7 expression using multiple tissue Northern blots, containing poly(A) + RNA from various tissues, demonstrate that mda-7 expression is restricted to the thymus, spleen and peripheral blood leukocytes (Figure 2 ). Previous studies document a 9712-fold elevation in mRNA expression of a gene c49a (a rat homologue of mda-7) during the process of wound healing (Soo et al., 1999) . Based on these observations, we evaluated a series of hematopoietic cells, representing erythroid, myeloid and lymphoid lineages, with and without induction of speci®c dierentiation programs for expression of mda-7. No de novo mda-7 expression was detected in HL-60 (human promyelocytic leukemia), K562 (human erythroleukemia), CEM-C7 (human T-cell leukemia) or a TPA-resistant variant of HL-60 (HL534) (Figure 2) . Similarly, induction of HL-60 dierentiation by treatment with TPA (monocyte/macrophage) or DMSO (granulocyte) or treatment of CEM-C7 cells with TPA did not induce mda-7 expression. However, treatment of K562 cells with TPA, which induces these cells to dierentiate into megakaryocytes, resulted in induction of mda-7 mRNA at levels similar to that found in HO-1 cells treated with IFNb+MEZ (Figure 2 ). If this increase in mda-7 correlates with an elevation of functional MDA-7 protein these results suggest that mda-7 might have a biological role in megakaryocytic dierentiation. Dierentiation of K562 leukemia cells by TPA treatment to megakaryocytic cells is characterized by an increase in platelet peroxidase positivity, enhancement of thromboxane A2 receptors and increased cell volume and DNA ploidy (reviewed in Alitalo, 1990) . There is also an increase in synthesis of platelet derived growth factor (PDGF) and transforming growth factor beta 1 (TGF-b1) two of the cytokines that mark the wound-healing process (Chu et al., 1999; Li et al., 1999; Miller, 1999) . The molecular function of mda-7 during this program of dierentia- : IFN-b+MEZ tion is unclear at this time, however, it is possible that mda-7 may have multiple biological roles including an involvement in immune responses and wound healing. Of particular relevance, mda-7 may have an indirect/direct role in platelet formation during erythroid cell dierentiation. At the time of initial isolation and characterization, computational analysis of MDA-7 indicated that it was a unique cDNA, showing no homology to known sequences in the databases or containing easily identi®able structural attributes or motifs at the peptide level (Jiang et al., 1994 (Jiang et al., , 1995b (Jiang et al., , 1996 . Among the reported protein domains present in the conceptually translated peptide sequence was an Interleukin-10 (IL-10) signature. Recent information (Chaiken and Williams, 1996; Kotenko et al., 2001 ; and unpublished data) strongly suggest that mda-7 belongs to the fourhelix bundle family cytokine molecules (Chaiken and Williams, 1996; Kotenko et al., 2001 ) most related to the IL-10 sub-family Xie et al., 2000; Kotenko et al., 2001) . In addition to IL-10, this protein family in humans presently includes IL-19, IL-TIF, AK-155 and IL-20. Although the extent of amino acid homology between members is not extensive (IL-10 and mda-7 share 520% sequence identity), several similarly related molecules have been discovered and from the collectively available information there is now convincing evidence to classify mda-7 as a member of the family (Gallagher et al., 2000; Xie et al., 2000; Zhang et al., 2000; Kotenko et al., 2001) . Two features of mda-7 in addition to the presence of an IL-10 family signature and predicted four-helix bundle protein conformation reinforce this idea. These features include a 49 amino acid N-terminal signal peptide classically present in secreted molecules and its location in the human genome on chromosome locus 1q32 where it shows tight linkage to other members of the family, including ing, what appears to be a cytokine cluster. It seems from presently documented literature, even for those members of the IL-10 family whose discovery was reported within the last year , that each member has a distinct set of functional attributes and tissue distribution. For example, IL-10 has a pleiotropic immunomodulatory eect and is produced in T-cell subsets, monocytes, keratinocytes and activated B-cells (Gallagher et al., 2000; Saito, 2000) . IL-19 is monocyte speci®c (Gallagher et al., 2000) and IL-20 is expressed at low levels in skin and certain other tissues (Blumberg et al., 2001) while mda-7 appears to be primarily restricted to peripheral blood leukocytes, thymus and spleens of normal adult humans at the RNA level (Figure 2 ). It appears from the presently available information that each protein has distinct non-overlapping biological eects, not entirely unexpected given the limited homology of primary amino acid sequence. Of these eector functions, the transformed cell speci®c inhibitory activity appears to be a property unique to mda-7. Given its signi®cant structural relatedness to IL-10 family cytokines and clustered location in the IL-10 genomic locus, studies directed toward understanding the cytokine related nature and properties of mda-7 is likely to yield important information pertaining to biological activity.
Materials and methods

Cell cultures and growth assays
A normal SV40 immortalized human foreskin melanocyte cell line, FM516-SV (FM516), was provided by Dr L Diamond (Wistar Institute, PA, USA). WM35, WM278 and WM239 were obtained from Dr M Herlyn (Wistar Institute, PA, USA) (Jiang et al., 1995a) . Metastatic FO-1 and HO-1 melanoma cells were described previously (Fisher et al., 1985) . C8161 metastatic melanoma cells were obtained from Dr D Welch (University of Pennsylvania) (Jiang et al., 1995a) . Dr RS Kerbel provided the MeWo cell line and its reduced metastatic variant 3S5 and highly metastatic variant 70W (Kerbel and Man, 1984; Graham et al., 1991) . SK-MEL p53 mt and SK-MEL p53 wt were provided by Dr A Albino (American Health Foundation, NY, USA). HBL-100, MCF-7, T47D, MDA-MB-157, MDA-MB-231, MDA-MB-453, LNCaP, PC-3, DU-145, HeLa, Saos2, MIA PaCa-2, PANC-1, BxPC-3, AsPC-1, T98G and HONE-1 cells were obtained from the American Type Culture Collection. NC, a normal human cerebellum astrocyte cell line and the GBM-18 human glioblastoma multiforme cell line were established in culture from patient-derived samples (Vita et al., 1988; Guarini et al., 1990) . Early passage normal human prostate epithelial cells (HuPEC) were obtained from Clonetics Inc. (CA, USA) and cultured using reagents and medium provided by the company. Most cell lines were grown in Dulbecco's modi®ed Eagle's minimum essential medium supplemented with 5 or 10% fetal bovine serum and antibiotics. The pancreatic carcinoma cell lines were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum. All cells were cultured at 378C in a humidi®ed 5% CO 2 95% air incubator. Growth assays were performed by seeding cells in complete growth medium at 1610 5 cells/35-mm plate and viable cell counts were determined by hemocytometer 48 and 96 h after a medium change without additions (control), 2000 units/ml of IFN-b, 10 ng/ml of MEZ or 2000 units/ml of IFN-b+10 ng/ml MEZ. Data is presented as average of triplicate samples which varied by 410%. An additional study was performed which varied by 415%.
Virus construction and plaque assays
The recombinant replication-defective Ad.mda-7 virus was created in two steps as described previously . Brie¯y, the coding region of the mda-7 gene was cloned into a modi®ed Ad expression vector pAd.CMV (Falck-Pedersen et al., 1994) . This vector contains, in order, the ®rst 355 bp from the left end of the Ad genome, the cytomegalovirus immediate early promoter, DNA encoding splice donor and acceptor sites, the coding region of the mda-7 cDNA, DNA encoding a poly(A) signal sequence from the b globin gene, and *3 kbp of adenovirus sequence extending from within the E1B coding region. This arrangement allows high-level expression of the cloned sequence by the cytomegalovirus immediate early gene promoter, and appropriate RNA processing (Falck-Pedersen et al., 1994) . The recombinant virus was created in vivo in 293 cells (Graham et al., 1977) by homologous recombination between mda-7-containing vector and plasmid JM17, which contains the whole of the Ad genome cloned into a modi®ed version of pBR322 (McGrory et al., 1988) . JM17 gives rise to Ad genomes in vivo but they are too large to package. This constraint is relieved by recombination with the vector to create a packageable genome (McGrory et al., 1988) , containing the mda-7 gene. The recombinant virus is replication defective in human cells except 293 cells, which express adenovirus E1A and E1B. Following transfection of the two plasmids, infectious virus was recovered, the genomes were analysed to con®rm the recombinant structure, and then virus was plaque puri®ed, all by standard procedures (Volkert and Young, 1983) .
Northern and Western blotting assays
Multiple-tissue Northern blots (Clontech) of poly(A) + mRNA extracted from dierent human tissues were hybridized in ExpressHyb solution (Clontech) with the coding region of the mda-7 cDNA. The normal tissue analysed included heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral blood leukocyte. The mda-7 probe was labeled with a-32 P-dCTP using a random primer labeling kit and membranes were washed according to manufacture's protocol (Amersham, IL, USA). Levels of mda-7 and GAPDH mRNA in untreated, IFNb+MEZ (2000 units/ml+10 ng/ml) treated or Ad.mda-7 infected cells were determined by Northern blotting analysis of total cytoplasmic RNA as previously described . In brief, 10 mg of total RNA from the dierent cell types were electrophoresed in 1% agarose gel, transferred to a nylon membrane, and hybridized with the dierent 32 Plabeled cDNA fragments. The membrane was stripped and hybridized with the indicated probes sequentially. Northern blots were washed in a 0.1% SDS, 16SSC buer at room temperature for 30 min followed by washing at 428C for an additional 30 min in the same buer. After hybridization, the nylon membranes were washed and exposed for autoradiography.
MDA-7 and elongation factor 1-alpha (EF-1a) protein levels were determined by Western blotting as described previously (Su et al., 1995) . Cells were grown in 100-cm plates and after appropriate treatment were washed twice with cold PBS and lysed on ice for 30 min in 100 ml of cold RIPA buer [50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.1% SDS, 1% NP40, and 0.5% sodium deoxycholate] with freshly added 0.1 mg/ml phenylmethylsulfonyl¯uoride, 1 mM sodium orthovanadate, and 1 mg/ml aprotinin. Cell debris were removed by centrifugation at 14 000 g for 10 min at 48C. Protein concentrations were determined using the Bio-Rad protein assay system (Bio-Rad Laboratories, Richmond, CA, USA). Aliquots of cell extracts containing 20 ± 50 mg of total protein were resolved in 12% SDS ± PAGE and transferred to Immobilon-P PVDF membranes (Millipore Corp., Bedford, MA, USA). Filters were blocked for 1 h at room temperature in Blotto A [5% nonfat milk powder in TBS-T: 10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.05% Tween 20], and then incubated for 1 h at room temperature in Blotto A containing a 1 : 1000 dilution of rabbit anti-MDA-7, polyclonal antibody. After washing in TBS-T buer (365 min, room temperature), ®lters were incubated for 45 min at room temperature in Blotto A containing a 1 : 10 000 dilution of corresponding peroxidase conjugated anti-rabbit secondary antibody (Amersham, Arlington Heights, IL, USA). After washing in TBS-T, ECL was performed according to the recommendation of the manufacturer.
Isolation of mda-7 genomic clones
Polymerase chain reaction ampli®cation Diploid human ®broblast DNA (Clontech) was used as a template with human mda-7 gene speci®c primers, (5'-primer) 5'-ACAA-GACATGACTGTGAGGAG-3' and (3'-primer) 5'-AGACTGTTTGAAATGACACAG-3'. The proof reading and high eciency Advantage Tth DNA polymerase (Clontech) was used in all reactions. The PCR cycling conditions were 958C/1 min, 608C/1 min and 728C/6 min. The reaction was processed for 30 cycles with an additional 728C/10 min extension performed at the end. The PCR reaction product was analysed by agarose gel electrophoresis and sequencing by the ABI method.
Library screening A human placental genomic lambda Fix II library (Stratagene, La Jolla, CA, USA) was screened using the human mda-7 cDNA. The probe was labeled with a-32 P-dCTP using a random primer labeling kit from Amersham according to manufacture's protocol. Plaque lift ®lters were hybridized overnight in hybridization buer (ExpressHyb, Clontech) at 688C. The ®lters were washed at 558C for 20 min, twice in 26SSC, 0.1% SDS buer, and once in 0.56SSC, 0.1% SDS buer and exposed to X-ray (Kodak) ®lm.
DNA sequencing of mda-7 human genomic clone The isolated phage DNA clones were mapped by restriction enzyme analysis using standard procedures (Sambrook et al., 1989) . PCR generated products were cloned into pBluescript and sequenced using universal primers with an ABI automatic sequencer model 372 (Applied Biosystems). DNA and protein sequence alignment were determined using the GCG software package (Wisconsin Package Version 10.0, Genetics Computer Group (GCG), Madison, WI, USA). The percentage of DNA and Protein sequence homology was determined using the GenBank database and GCG homology algorithms including BLAST, FATSA, BESTFIT and GAP.
Chromosomal mapping of the human mda-7 gene
For chromosomal mapping studies, oligonucleotides for generating PCR products were designed using the computer program Oligo 4.0 (National Biosciences) based on the mda-7 sequence (Jiang et al., 1995b) . The two primers used to amplify a 129 bp human mda-7 speci®c gene product were: MDA7F, 5'GGTTTGTTCCCTGTGTCATT3' and MDA7R, 5'GCGCTGCTTAAAGAATGACT3'. These primer sets were used with PCR to determine the presence or absence of the mda-7 locus in a panel of 19 rodent-human hybrids. PCR reactions were conducted in a ®nal volume of 12.5 ml with 100 ng of template, 20 ng primers, 10 mM tris-HCL pH 8.3, 50 mM KCl, 0.1 mg/ml gelatin, 15 mM MgCl 2 , 200 mM dNTPs and 0.5 U Taq polymerase. Ampli®cations were performed in a Perkin-Elmer Cetus 9600 thermal cycler for 30 cycles at 948C for 30 s, 588C for 30 s and 728C for 30 s. The PCR products were visualized in ethidium bromide stained 1.5% agarose gels. The ampli®cation product was puri®ed with Qiagen PCR puri®cation kit, and 1 ng of DNA and 20 ng speci®c primer used with the Taq Dye Deoxy Terminator Cycle Sequencing Kit (ABI). The reaction products were electrophoresed and recorded on the 377 DNA sequencer (ABI).
